Evaluation of Bone Formation Marker Changes in Summit, A Trial Assessing Bezuclastinib in Adults With Non-Advanced Systemic Mastocytosis: An Exploratory Analysis

Dr Nathan Boggs discusses exploratory Summit trial data showing that bezuclastinib may improve bone remodeling, bone mineral density, and T-scores in patients with non-advanced systemic mastocytosis, supporting its potential disease-modifying effects.

Bezuclastinib is an investigational therapy. It has not been approved by the FDA or any regulatory authority.

Nathan Boggs, MD, PhD, is an associate professor of medicine and the Allergy Division director at the F. Edward Hebert School of Medicine, Uniformed Services University, in Bethesda, MD. He is also a staff allergist immunologist at Walter Reed Medical Center. Dr Boggs completed allergy immunology fellowship at the National Institutes of Health, internal medicine residency at Yale-New Haven Hospital, an MD at the Uniformed Services University, a PhD in plant molecular biology and genetics at Cornell University, and a BS at the University of Vermont.   

Dr Boggs leads a research team and laboratory investigating both the impact of KIT mutations on different clinical phenotypes and the role of tryptase in chronic urticaria. The research team combines next-generation sequencing with laboratory-based functional testing to link genotypes with phenotypes. Dr Boggs is the site principal investigator on multiple investigational product clinical trials for systemic mastocytosis at Walter Reed including: NCT05186753, NCT06915766, and NCT04655118. He developed a TRICARE screening and diagnosis registry to reduce the time to diagnosis and improve the care of patients with systemic mastocytosis. Dr Boggs also developed clinical and research collaborations with ARUP labs and the National Institutes of Health (NIH) Clinical Center.